These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 4711734)

  • 21. Absence of IgA antibody to herpesvirus in cervicovaginal secretions of patients with carcinoma of the cervix.
    Dent PB; Bienenstock J
    Clin Immunol Immunopathol; 1974 Nov; 3(2):171-7. PubMed ID: 4615850
    [No Abstract]   [Full Text] [Related]  

  • 22. Incidence of antibody to envelope antigen of herpes simplex virus type 2 among patients with cervical carcinoma and matched controls.
    Feorino PM; Palmer EL
    J Infect Dis; 1973 Jun; 127(6):732-5. PubMed ID: 4350521
    [No Abstract]   [Full Text] [Related]  

  • 23. Antibodies to herpesvirus type 2 in breast cancer and cervical cancer patients.
    Adam E; Sanders EK; Melnick JL; Levy AH; Rawls WE
    Cancer; 1974 Jan; 33(1):147-52. PubMed ID: 4810088
    [No Abstract]   [Full Text] [Related]  

  • 24. Cervical cancer in Yugoslavia. I. Antibodies to genital herpesvirus in cases and controls.
    Kessler II; Kulcar Z; Rawls WE; Smerdel S; Strnad M; Lilienfeld AM
    J Natl Cancer Inst; 1974 Feb; 52(2):369-76. PubMed ID: 4816000
    [No Abstract]   [Full Text] [Related]  

  • 25. Herpes type-2 virus antigens in human cervical carcinoma.
    Adelusi B; Osunkoya BO; Fabiyi A
    Obstet Gynecol; 1976 May; 47(5):545-8. PubMed ID: 772507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elution of herpes simplex virus-specific cytotoxic antibodies from squamous cell carcinoma of uterine cervix.
    Seth P; Balachandran N
    Nature; 1980 Aug; 286(5773):613-5. PubMed ID: 6250079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative diagnostic aspects of herpes simplex virus tumor-associated antigens.
    Notter MF; Docherty JJ
    J Natl Cancer Inst; 1976 Sep; 57(3):483-8. PubMed ID: 185398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seroepidemiologic studies of herpesvirus type 2 and carcinoma of the cervix. IV. Dysplasia and carcinoma in situ.
    Adam E; Kaufman RH; Melnick JL; Levy AH; Rawls WE
    Am J Epidemiol; 1973 Aug; 98(2):77-87. PubMed ID: 4724998
    [No Abstract]   [Full Text] [Related]  

  • 29. [Investigations concerning the evidence of herpes simplex virus type 2 (HSV-2) antibodies in patients with carcinoma of the cervix (author's transl)].
    Dostal V; Fanta D; Reiss-Gutfreund RJ; Janisch H; Berger R
    Wien Klin Wochenschr; 1977 Mar; 89(6):201-3. PubMed ID: 191994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies of tumor-specific and herpesvirus nonvirion antigens.
    Hollinshead A; Tarro G; Foster WA; Seigel LJ; Jaffurs W
    Cancer Res; 1974 May; 34(5):1122-5. PubMed ID: 4842911
    [No Abstract]   [Full Text] [Related]  

  • 31. Herpes viruses and oncogenesis.
    Klein G
    Johns Hopkins Med J Suppl; 1974; 3():15-25. PubMed ID: 4370988
    [No Abstract]   [Full Text] [Related]  

  • 32. Humoral-and cell-mediated immune responses to herpesvirus antigens in patients with cervical carcinoma.
    Kumar A; Selim MS; Madden DL; Wallen WC; Vasquez HH; Nankervis GA
    Gynecol Oncol; 1980 Aug; 10(1):18-25. PubMed ID: 6249698
    [No Abstract]   [Full Text] [Related]  

  • 33. Association of herpes simplex type 2 virus with cervical cancer of the uterus.
    Kao CL; Chen YH; Tang MC; Wen HK; Hsia S
    Taiwan Yi Xue Hui Za Zhi; 1974 Feb; 73(2):122-7. PubMed ID: 4368434
    [No Abstract]   [Full Text] [Related]  

  • 34. Measurement of antibodies to herpesvirus types 1 and 2 in human sera by microradioimmunoassay.
    Jankowski MA; Petersen EE; Böcker JF
    Acta Virol; 1977 Sep; 21(5):405-11. PubMed ID: 22235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum antibodies to the major HSV-2-specified DNA-binding protein in patients with an acute HSV infection or cervical neoplasia.
    Lehtinen M; Lehtinen T; Koivisto V; Paavonen J; Leinikki P
    J Med Virol; 1985 Jul; 16(3):245-56. PubMed ID: 2993495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variations of cytotoxic antibodies to cells with herpes simplex virus antigens in women with progressing or regressing cancerous lesions of the cervix.
    Thiry L; Sprecher-Goldberger S; Fassin Y; Gould I; Gompel C; Pestiau J; De Halleux F
    Am J Epidemiol; 1974 Oct; 100(4):251-61. PubMed ID: 4370721
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunodiagnostic potential of a virus-coded, tumor-associated antigen (AG-4) in cervical cancer.
    Aurelian L; Strnad BC; Smith MF
    Cancer; 1977 Apr; 39(4 Suppl):1834-49. PubMed ID: 192436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence and expression of the herpes simplex virus type 2 genome in cervical tumor cells.
    Aurelian L
    Clin Orthop Relat Res; 1974; (99):78-85. PubMed ID: 4363067
    [No Abstract]   [Full Text] [Related]  

  • 39. Persistence and expression of the herpes simplex virus type 2 genome in cervical tumor cells.
    Aurelian L
    Cancer Res; 1974 May; 34(5):1126-35. PubMed ID: 4367156
    [No Abstract]   [Full Text] [Related]  

  • 40. Onocogenic conversion of normal cells by inactivated herpes simplex viruses.
    Rapp F; Duff R
    Cancer; 1974 Oct; 34(4 Suppl):suppl:1353-62. PubMed ID: 4371360
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.